{"id":"https://genegraph.clinicalgenome.org/r/a23287df-0ccd-443a-b883-d0acbe106c5av1.1","type":"EvidenceStrengthAssertion","dc:description":"FOXA2 was first reported in relation to autosomal dominant combined pituitary hormone deficiencies in 2017 (Giri et al., PMID: 28973288). Six variants (5 missense, 1 nonsense) that have been reported in six probands in five publications (PMIDs: 28973288, 29329447, 30414530, 33729509, 31294511) are included in this curation. Variants were reported to be de novo for all cases in which parents were available for testing; for two of the missense variants, supporting evidence for reduced function is available (PMIDs: 28973288, 29329447). Thus far, reported missense variants appear to cluster in or near the forkhead domain, which may affect the DNA binding ability of this transcriptional activator (PMID: 33729509). At least two probands with a similar phenotype and de novo deletions encompassing FOXA2 have been reported, but were not scored in this curation (PMIDs: 31294511, 32277595). Therefore, the mechanism of pathogenicity appears to be LOF leading to haploinsufficiency. This gene-disease association is also supported by expression studies in both mouse and human embryos (PMID: 28973288). In summary, there is moderate evidence to support the relationship between FOXA2 and autosomal dominant combined pituitary hormone deficiencies. This classification was approved by the ClinGen Brain Malformations gene curation expert panel on 22.Nov.2022.  ","dc:isVersionOf":"https://genegraph.clinicalgenome.org/r/a23287df-0ccd-443a-b883-d0acbe106c5a","GCISnapshot":"https://genegraph.clinicalgenome.org/r/8a995738-1ea3-454b-b92f-251d4b21d530","calculatedEvidenceStrength":"Moderate","contributions":[{"id":"https://genegraph.clinicalgenome.org/r/8a995738-1ea3-454b-b92f-251d4b21d530_contrib","agent":"https://genegraph.clinicalgenome.org/agent/10020","date":"2022-11-22T20:00:00.000Z","role":"Approver"},{"id":"https://genegraph.clinicalgenome.org/r/8a995738-1ea3-454b-b92f-251d4b21d530_publish_contrib","agent":"https://genegraph.clinicalgenome.org/agent/10020","date":"2023-02-13T17:21:40.497Z","role":"Publisher"}],"evidence":[{"id":"https://genegraph.clinicalgenome.org/r/8a995738-1ea3-454b-b92f-251d4b21d530_experimental_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/8a995738-1ea3-454b-b92f-251d4b21d530_functional_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/595bb1ec-cde8-4bfc-ac93-b08219060cc3","type":"EvidenceLine","dc:description":"While expression studies are not typically scored for genes expressed in the brain, the BM GCEP chose to score this evidence, albeit at a lower score, given the specificity of the expression and its relevance to the patient phenotype.","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/6ecf742d-a134-454b-83eb-87b68fe2a588","type":"Finding","dc:description":"Foxa2 mRNA transcripts were detected in the midbrain, ventral forebrain, ventral hindbrain, epithelial structures lining the main bronchus, lungs and the esophagus from embryonic day e11.5; and in the anterior lobe of the pituitary gland from e13.5. From e15.5, Foxa2 mRNA expression was stronger with robust expression in the ventral diencephalon, and anterior lobe of the pituitary gland. At embryonic day e18.5, Foxa2 mRNA transcripts were localized in the hypothalamic-pituitary axis, with transcripts strongly expressed in the ventral hypothalamus and anterior pituitary. ","dc:source":"https://pubmed.ncbi.nlm.nih.gov/28973288","rdfs:label":"Expression of Foxa2 mRNA in mouse embryonic development","demonstrates":{"id":"cg:GeneExpressionA"}}],"specifiedBy":"GeneValidityGeneExpressionCriteria","strengthScore":0.25},{"id":"https://genegraph.clinicalgenome.org/r/09838711-85b1-40a6-ad59-6f3ac60ade0a","type":"EvidenceLine","dc:description":"While expression studies are not typically scored for genes expressed in the brain, the BM GCEP chose to score this evidence, albeit at a lower score, given the specificity of the expression and its relevance to the patient phenotype","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/2195f1ed-e85a-4966-ac73-750acad9fe15","type":"Finding","dc:description":"Expression of hFOXA2 in the ventral neural tube and diencephalon at six weeks and around the third ventricle at 8 weeks. hFOXA2 was speciï¬cally localized in the cytoplasm of cells scattered in the pancreatic parenchyma at 13 weeks of gestation.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/28973288","rdfs:label":"FOXA2 expression in human embryos by IHC","demonstrates":{"id":"cg:GeneExpressionA"}}],"specifiedBy":"GeneValidityGeneExpressionCriteria","strengthScore":0.25}],"specifiedBy":"GeneValidityOverallFunctionalEvidenceCriteria","strengthScore":0.5}],"specifiedBy":"GeneValidityOverallExperimentalEvidenceCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/8a995738-1ea3-454b-b92f-251d4b21d530_overall_genetic_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/59c0f1cd-cb6e-4242-94ed-30152ddfbb0a","type":"EvidenceLine","dc:description":"The BM GCEP chose to upgrade by 0.5 pts, missense variants located with the forkhead domain (aa164-250) of this gene as these may affect the DNA binding ability of this transcriptional activator.","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/59c0f1cd-cb6e-4242-94ed-30152ddfbb0a_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/30414530","allele":{"id":"https://genegraph.clinicalgenome.org/r/b821c19b-5474-4851-a284-9589e3f3faee","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_021784.5(FOXA2):c.664T>C (p.Cys222Arg)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA408502020"}},"alleleOrigin":{"id":"cg:DeNovoAlleleOrigin"},"paternityMaternityConfirmed":"Yes","zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":1},{"id":"https://genegraph.clinicalgenome.org/r/18009bd6-e89f-49b5-ab5c-fa78194cc797","type":"EvidenceLine","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/18009bd6-e89f-49b5-ab5c-fa78194cc797_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/31294511","allele":{"id":"https://genegraph.clinicalgenome.org/r/e59122e1-4749-44ee-be75-efaa1f374d57","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_021784.5(FOXA2):c.766C>A (p.Arg256Ser)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA408501787"}},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.1},{"id":"https://genegraph.clinicalgenome.org/r/398f1305-2fcf-4ad2-8fb8-a2f78c753184","type":"EvidenceLine","calculatedScore":1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/398f1305-2fcf-4ad2-8fb8-a2f78c753184_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/29329447","allele":{"id":"https://genegraph.clinicalgenome.org/r/68cc92d0-c8c2-42b8-8a22-3ef214a7adbc","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_021784.5(FOXA2):c.770G>T (p.Arg257Leu)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA408501778"}},"alleleOrigin":{"id":"cg:DeNovoAlleleOrigin"},"paternityMaternityConfirmed":"No","zygosity":{"id":"cg:Heterozygous"}},{"id":"https://genegraph.clinicalgenome.org/r/398f1305-2fcf-4ad2-8fb8-a2f78c753184_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"Site-directed mutagenesis was performed to recreate the mutation in a WT human FOXA2 expression plasmid. Mutant and WT human FOXA2 were expressed in 293T cells, and protein levels were evaluated by Western blot analysis. Expression levels were slightly lower for mutant compared with WT Foxa2. uciferase reporter assay was developed to define the ability of mutant Foxa2 to transactivate target genes that are important for beta cell and pituitary devel-opment and function. Transactivation of all genes studied by mutant Foxa2 was substantially decreased compared with WT Foxa2","functionalDataSupport":"Yes"}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":1},{"id":"https://genegraph.clinicalgenome.org/r/8d4ddf89-1b70-48bd-aafb-d171e2d3b101","type":"EvidenceLine","calculatedScore":1.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/8d4ddf89-1b70-48bd-aafb-d171e2d3b101_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/33729509","allele":{"id":"https://genegraph.clinicalgenome.org/r/8ba6f562-eb0a-45e3-b270-bf2eb1e189b0","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_021784.5(FOXA2):c.686C>A (p.Ser229Ter)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA408501971"}},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":1.5},{"id":"https://genegraph.clinicalgenome.org/r/4e6498ac-16ea-472a-8c3e-4175bc30903a","type":"EvidenceLine","dc:description":"The BM GCEP chose to upgrade by 0.5 pts, missense variants located with the forkhead domain (aa164-250) of this gene as these may affect the DNA binding ability of this transcriptional activator.","calculatedScore":1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/4e6498ac-16ea-472a-8c3e-4175bc30903a_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/28973288","allele":{"id":"https://genegraph.clinicalgenome.org/r/e7084121-3a07-4056-9e8f-55885bc2f6dc","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_021784.5(FOXA2):c.505T>C (p.Ser169Pro)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA408502395"}},"alleleOrigin":{"id":"cg:DeNovoAlleleOrigin"},"paternityMaternityConfirmed":"Yes","zygosity":{"id":"cg:Heterozygous"}},{"id":"https://genegraph.clinicalgenome.org/r/4e6498ac-16ea-472a-8c3e-4175bc30903a_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"Transient transfection of HEK293T cells with Wt (Wild type) hFOXA2 or mutant hFOXA2 showed\nan impairment in transcriptional reporter activity by the mutant hFOXA2. Further analyses using western blot assays showed that the FOXA2 p.(S169P) variant is pathogenic resulting in lower expression levels when compared with Wt hFOXA2.","functionalDataSupport":"Yes"}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":1.5},{"id":"https://genegraph.clinicalgenome.org/r/d9c63522-07e8-4a3b-be93-f4b0b322362d","type":"EvidenceLine","dc:description":"The BM GCEP chose to upgrade by 0.5 pts, missense variants located with the forkhead domain (aa164-250) of this gene as these may affect the DNA binding ability of this transcriptional activator","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/d9c63522-07e8-4a3b-be93-f4b0b322362d_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/33729509","allele":{"id":"https://genegraph.clinicalgenome.org/r/caa41858-c3dc-4289-bf8d-8ce0d79b2b72","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_021784.5(FOXA2):c.682C>A (p.Arg228Ser)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA408501980"}},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.5}],"specifiedBy":"GeneValidityOverallGeneticEvidenceCriteria","strengthScore":5.6}],"evidenceStrength":"Moderate","sequence":5885,"specifiedBy":"GeneValidityCriteria9","strengthScore":6.1,"subject":{"id":"https://genegraph.clinicalgenome.org/r/3f6D6PruiDU","type":"GeneValidityProposition","disease":"obo:MONDO_0013099","gene":"hgnc:5022","modeOfInheritance":"obo:HP_0000006"},"version":"1.1","websiteLegacyID":"https://genegraph.clinicalgenome.org/r/assertion_8a995738-1ea3-454b-b92f-251d4b21d530-","@context":{"@vocab":"https://genegraph.clinicalgenome.org/terms/","id":"@id","type":"@type","cg":"https://genegraph.clinicalgenome.org/terms/","dc":"http://purl.org/dc/terms/","obo":"http://purl.obolibrary.org/obo/","hgnc":"https://identifiers.org/hgnc:","rdfs":"http://www.w3.org/2000/01/rdf-schema#","cggv":"https://genegraph.clinicalgenome.org/r/gci/","evidenceStrength":{"@type":"@vocab"},"calculatedEvidenceStrength":{"@type":"@vocab"},"computedEvidenceStrength":{"@type":"@vocab"},"specifiedBy":{"@type":"@vocab"},"evidence":{"@container":"@set"},"disease":{"@type":"@vocab"},"gene":{"@type":"@vocab"},"phenotypes":{"@type":"@id"},"agent":{"@type":"@id"},"role":{"@type":"@vocab"},"modeOfInheritance":{"@type":"@vocab"},"sex":{"@type":"@vocab"},"direction":{"@type":"@vocab"},"ageType":{"@type":"@vocab"},"ageUnit":{"@type":"@vocab"},"dc:source":{"@type":"@id"},"curationReasons":{"@type":"@vocab","@container":"@set"},"GCISnapshot":{"@type":"@id"},"dc:isVersionOf":{"@type":"@id"},"websiteLegacyID":{"@type":"@id"}}}